新型β-内酰胺类药物对脆弱拟杆菌群成员的比较活性
Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group.
作者信息
Cuchural G J, Tally F P, Jacobus N V, Cleary T, Finegold S M, Hill G, Iannini P, O'Keefe J P, Pierson C
机构信息
Department of Medicine, Tufts-New England Medical Center Hospitals, Boston, Massachusetts 02111.
出版信息
Antimicrob Agents Chemother. 1990 Mar;34(3):479-80. doi: 10.1128/AAC.34.3.479.
Abstract
A nationwide susceptibility survey of 557 isolates of the Bacteroides fragilis group was continued in 1986. The most active beta-lactam drugs were imipenem and ticarcillin-clavulanic acid, which had 0.2 and 1.7% resistance, respectively. The rank order of activity of beta-lactam drugs was imipenem, ticarcillin-clavulanic acid, cefoxitin, piperacillin, moxalactam, ceftizoxime, cefotetan, cefotaxime, cefoperazone, and ceftazadime.
摘要
1986年继续对557株脆弱拟杆菌属菌株进行了一项全国性药敏调查。活性最强的β-内酰胺类药物是亚胺培南和替卡西林-克拉维酸，其耐药率分别为0.2%和1.7%。β-内酰胺类药物的活性排序为亚胺培南、替卡西林-克拉维酸、头孢西丁、哌拉西林、拉氧头孢、头孢唑肟、头孢替坦、头孢噻肟、头孢哌酮和头孢他啶。
相似文献
1
Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group.新型β-内酰胺类药物对脆弱拟杆菌群成员的比较活性
Antimicrob Agents Chemother. 1990 Mar;34(3):479-80. doi: 10.1128/AAC.34.3.479.
2
Newer beta-lactam agents and the Bacteroides fragilis group.新型β-内酰胺类药物与脆弱拟杆菌群
Pharmacotherapy. 1991;11(2 ( Pt 2)):51S-55S.
3
Activity of newer beta-lactam agents against clinical isolates of Bacteroides fragilis and other Bacteroides species.新型β-内酰胺类药物对脆弱拟杆菌及其他拟杆菌属临床分离株的活性。
Antimicrob Agents Chemother. 1987 Dec;31(12):2002-4. doi: 10.1128/AAC.31.12.2002.
4
The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.1987年美国脆弱拟杆菌群的抗菌药敏模式。
J Antimicrob Chemother. 1990 Jun;25(6):1011-9. doi: 10.1093/jac/25.6.1011.
5
Survey of Bacteroides fragilis group susceptibility patterns in Canada.加拿大脆弱拟杆菌群药敏模式调查。
Antimicrob Agents Chemother. 1992 Feb;36(2):343-7. doi: 10.1128/AAC.36.2.343.
6
Susceptibility of 114 isolates of the Bacteroides fragilis group to imipenem and eight other antimicrobial agents.114株脆弱拟杆菌属菌株对亚胺培南及其他8种抗菌药物的敏感性
Pathology. 1988 Jul;20(3):260-3. doi: 10.3109/00313028809059504.
7
In-vitro activity of amoxycillin and ticarcillin in combination with clavulanic acid compared with that of new beta-lactam agents against species of the Bacteroides fragilis group.阿莫西林和替卡西林与克拉维酸联合使用的体外活性与新型β-内酰胺类药物针对脆弱拟杆菌群各菌种的活性比较。
J Antimicrob Chemother. 1986 May;17(5):593-603. doi: 10.1093/jac/17.5.593.
8
Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989.1989年美国脆弱拟杆菌群的抗菌药敏模式
Clin Ther. 1992 Jan-Feb;14(1):122-36.
9
In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents.对头孢西丁/头孢替坦耐药的脆弱拟杆菌群菌株对各种其他抗菌剂敏感性的体外研究。
J Antimicrob Chemother. 1990 Sep;26(3):353-9. doi: 10.1093/jac/26.3.353.
10
In vitro activities of 36 antimicrobial agents against clinically isolated Bacteroides fragilis.36种抗菌剂对临床分离脆弱拟杆菌的体外活性
J Formos Med Assoc. 1991 Aug;90(8):796-9.
引用本文的文献
1
Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.1995年至1996年脆弱拟杆菌群体外药敏的多中心研究，以及1990年至1996年耐药趋势比较
Antimicrob Agents Chemother. 1999 Oct;43(10):2417-22. doi: 10.1128/AAC.43.10.2417.
2
In vitro activity of FK037, a new parenteral cephalosporin, against anaerobic bacteria.新型胃肠外头孢菌素FK037对厌氧菌的体外活性
Antimicrob Agents Chemother. 1993 May;37(5):957-61. doi: 10.1128/AAC.37.5.957.
3
Rationale for selective use of anaerobic blood cultures.选择性使用厌氧血培养的基本原理。
J Clin Microbiol. 1993 Aug;31(8):2110-3. doi: 10.1128/jcm.31.8.2110-2113.1993.
4
5
Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers.在三个医学中心对脆弱拟杆菌群的物种对五种抗菌药物的敏感性进行的纵向研究。
Antimicrob Agents Chemother. 1994 Oct;38(10):2276-9. doi: 10.1128/AAC.38.10.2276.
6
Comparison of the inoculum effect of cefoxitin and other cephalosporins and of beta-lactamase inhibitors and their penicillin-derived components on the Bacteroides fragilis group.头孢西丁与其他头孢菌素以及β-内酰胺酶抑制剂及其青霉素衍生成分对脆弱拟杆菌属的接种物效应比较。
Antimicrob Agents Chemother. 1991 Sep;35(9):1868-74. doi: 10.1128/AAC.35.9.1868.
7
Susceptibility testing of anaerobic bacteria: myth, magic, or method?厌氧菌的药敏试验：神话、魔法还是方法？
Clin Microbiol Rev. 1991 Oct;4(4):470-84. doi: 10.1128/CMR.4.4.470.
8
In vitro susceptibilities of the Bacteroides fragilis group to 14 antimicrobial agents in Korea.韩国脆弱拟杆菌群对14种抗菌药物的体外敏感性
Antimicrob Agents Chemother. 1992 Jan;36(1):195-7. doi: 10.1128/AAC.36.1.195.
9
Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989.1979 - 1989年间脆弱拟杆菌属菌群对各种抗菌药物敏感性的变化
Eur J Clin Microbiol Infect Dis. 1992 Apr;11(4):352-6. doi: 10.1007/BF01962077.
10
Antibiotic sensitivity of the Bacteroides fragilis group in Europe. European Study Group.欧洲脆弱拟杆菌群的抗生素敏感性。欧洲研究小组。
Eur J Clin Microbiol Infect Dis. 1992 Apr;11(4):292-304. doi: 10.1007/BF01962068.
本文引用的文献
1
Antibacterial activity of new beta-lactam antibiotics on cefoxitin-resistant strains of Bacteroides fragilis.
J Antimicrob Chemother. 1980 Mar;6(2):207-16. doi: 10.1093/jac/6.2.207.
2
Susceptibility of the Bacteroides fragilis group in the United States in 1981.1981年美国脆弱拟杆菌群的药敏情况。
Antimicrob Agents Chemother. 1983 Apr;23(4):536-40. doi: 10.1128/AAC.23.4.536.
3
Improved localization and survival in patients with intraabdominal abscesses.腹腔内脓肿患者定位及生存率的改善
Am J Surg. 1983 Jan;145(1):136-42. doi: 10.1016/0002-9610(83)90180-0.
4
Cefoxitin inactivation by Bacteroides fragilis.脆弱拟杆菌对头孢西丁的灭活作用。
Antimicrob Agents Chemother. 1983 Dec;24(6):936-40. doi: 10.1128/AAC.24.6.936.
5
Comparative study of parenteral piperacillin and cefoxitin in the treatment of surgical infections of the abdomen.
Surg Gynecol Obstet. 1983 Nov;157(5):423-5.
6
Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982.美国1292株脆弱拟杆菌属细菌的药敏情况：1981年与1982年的比较
Antimicrob Agents Chemother. 1984 Aug;26(2):145-8. doi: 10.1128/AAC.26.2.145.
7
Mechanisms of resistance and resistance transfer in anaerobic bacteria: factors influencing antimicrobial therapy.厌氧菌的耐药机制及耐药性转移：影响抗菌治疗的因素
Rev Infect Dis. 1984 Mar-Apr;6 Suppl 1:S260-9. doi: 10.1093/clinids/6.supplement_1.s260.
8
Anaerobic infections. 1.厌氧感染。1.
N Engl J Med. 1974 May 23;290(21):1177-84. doi: 10.1056/NEJM197405232902106.
9
Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States.美国全国范围内脆弱拟杆菌群药敏性研究。
Antimicrob Agents Chemother. 1985 Nov;28(5):675-7. doi: 10.1128/AAC.28.5.675.
10
Randomized, prospective, and double-blind trial of new beta-lactams in the treatment of appendicitis.新型β-内酰胺类药物治疗阑尾炎的随机、前瞻性、双盲试验
Antimicrob Agents Chemother. 1985 Nov;28(5):639-42. doi: 10.1128/AAC.28.5.639.
Zotero 插件